Last reviewed · How we verify
NCT06904365: OvAR-Y
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
trial testing HyperSight cone beam computed tomography (CBCT) scan in Uterine Cancer in 10 participants. Currently enrolling.
15 April 2026
Quick facts
| Lead sponsor | Washington University School of Medicine |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 10 |
| Start date | 8 April 2025 |
| Primary completion | 15 April 2026 |
| Estimated completion | 15 April 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- HyperSight cone beam computed tomography (CBCT) scan
- ETHOS 2.0
Conditions studied
- Uterine Cancer — all drugs for Uterine Cancer →
- Rectal Cancer — all drugs for Rectal Cancer →
- Colon Cancer — all drugs for Colon Cancer →
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Washington University School of Medicine
Who can join
Adults 18 to 50, female only, with Uterine Cancer or Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Female patients with early onset (\<50 years old) pelvic malignancies such as uterine and rectal cancers are rising in incidence, which often requires pelvic radiation; many of these patients are premenopausal and at a high risk of premature ovarian failure from radiotherapy. Premature ovarian failure carries significant cardiac, musculoskeletal, sexual, and psychosocial morbidity. Ovarian transposition carries variable success rates, is not readily accessible to the general population, and can still be at risk of clinically significant radiotherapy doses. There is an unmet need for innovative techniques to protect ovarian function.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Young lung cancer: from diagnosis to survivorship.
Florez N, Kiel L, Kaufman R, LoPiccolo J, et al · · 2025 · PMID 40641929 · DOI 10.3389/fonc.2025.1570143
Verify or expand the search:
- PubMed search for NCT06904365
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Uterine Cancer
Currently open trials in the same condition.
- NCT06795009 — Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer · Phase 1 · recruiting
- NCT06369155 — Azenosertib in Uterine Serous Carcinoma: Biomarker Study · Phase 2 · recruiting
- NCT06677190 — Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin · Phase 2 · recruiting
- NCT06527157 — Investigations of Reproductive Cancers in Women · recruiting
- NCT05916196 — [18F]FES PET/.CT in Uterine Cancer · Phase 2 · recruiting
Other Washington University School of Medicine trials
Trials by the same sponsor.
- NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
- NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
- NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
- NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06904365 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
- Last refreshed: 22 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06904365.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing